BACKGROUND AND OBJECTIVES: Little is known about renal function and blood pressure (BP) in long-term childhood cancer survivors. This cross-sectional study evaluated prevalence of these outcomes and associated risk factors in long-term childhood cancer survivors at their first visit to a specialized outpatient clinic. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Estimated GFR; percentages of patients with albuminuria, hypomagnesemia, and hypophosphatemia; and BP were assessed in 1442 survivors ≥5 years after diagnosis. Multivariable logistic regression analyses were used to estimate effect of chemotherapy, nephrectomy, and radiation therapy on the different outcomes. RESULTS: At a median age of 19.3 years (interquartile range, 15.6-24.5 years), 28.1% of all survivors had at least one renal adverse effect or elevated BP. The median time since cancer diagnosis was 12.1 years (interquartile range, 7.8-17.5 years). High BP and albuminuria were most prevalent, at 14.8% and 14.5%, respectively. Sixty-two survivors (4.5%) had an estimated GFR <90 ml/min per 1.73 m(2). Survivors who had undergone nephrectomy had the highest risk for diminished renal function (odds ratio, 8.6; 95% confidence interval [CI], 3.4-21.4). Combined radiation therapy and nephrectomy increased the odds of having elevated BP (odds ratio, 4.92; 95% CI, 2.63-9.19), as did male sex, higher body mass index, and longer time since cancer treatment. CONCLUSION: Almost 30% of survivors had renal adverse effects or high BP. Therefore, monitoring of renal function in high-risk groups and BP in all survivors may help clinicians detect health problems at an early stage and initiate timely therapy to prevent additional damage.
BACKGROUND AND OBJECTIVES: Little is known about renal function and blood pressure (BP) in long-term childhood cancer survivors. This cross-sectional study evaluated prevalence of these outcomes and associated risk factors in long-term childhood cancer survivors at their first visit to a specialized outpatient clinic. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Estimated GFR; percentages of patients with albuminuria, hypomagnesemia, and hypophosphatemia; and BP were assessed in 1442 survivors ≥5 years after diagnosis. Multivariable logistic regression analyses were used to estimate effect of chemotherapy, nephrectomy, and radiation therapy on the different outcomes. RESULTS: At a median age of 19.3 years (interquartile range, 15.6-24.5 years), 28.1% of all survivors had at least one renal adverse effect or elevated BP. The median time since cancer diagnosis was 12.1 years (interquartile range, 7.8-17.5 years). High BP and albuminuria were most prevalent, at 14.8% and 14.5%, respectively. Sixty-two survivors (4.5%) had an estimated GFR <90 ml/min per 1.73 m(2). Survivors who had undergone nephrectomy had the highest risk for diminished renal function (odds ratio, 8.6; 95% confidence interval [CI], 3.4-21.4). Combined radiation therapy and nephrectomy increased the odds of having elevated BP (odds ratio, 4.92; 95% CI, 2.63-9.19), as did male sex, higher body mass index, and longer time since cancer treatment. CONCLUSION: Almost 30% of survivors had renal adverse effects or high BP. Therefore, monitoring of renal function in high-risk groups and BP in all survivors may help clinicians detect health problems at an early stage and initiate timely therapy to prevent additional damage.
Authors: A M Fredriks; S van Buuren; R J Burgmeijer; J F Meulmeester; R J Beuker; E Brugman; M J Roede; S P Verloove-Vanhorick; J M Wit Journal: Pediatr Res Date: 2000-03 Impact factor: 3.756
Authors: W Stöhr; M Paulides; S Bielack; H Jürgens; E Koscielniak; R Rossi; T Langer; J D Beck Journal: Pediatr Blood Cancer Date: 2007-02 Impact factor: 3.167
Authors: Maud M Geenen; Mathilde C Cardous-Ubbink; Leontien C M Kremer; Cor van den Bos; Helena J H van der Pal; Richard C Heinen; Monique W M Jaspers; Caro C E Koning; Foppe Oldenburger; Nelia E Langeveld; Augustinus A M Hart; Piet J M Bakker; Huib N Caron; Flora E van Leeuwen Journal: JAMA Date: 2007-06-27 Impact factor: 56.272
Authors: Gemma Gatta; Giulia Zigon; Riccardo Capocaccia; Jan Willem Coebergh; Emmanuel Desandes; Peter Kaatsch; Guido Pastore; Rafael Peris-Bonet; Charles A Stiller Journal: Eur J Cancer Date: 2009-02-21 Impact factor: 9.162
Authors: Karen Wasilewski-Masker; Sue C Kaste; Melissa M Hudson; Natia Esiashvili; Leonard A Mattano; Lillian R Meacham Journal: Pediatrics Date: 2008-03 Impact factor: 7.124
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Rodrigo B Interiano; Noel Delos Santos; Sujuan Huang; Deo Kumar Srivastava; Leslie L Robison; Melissa M Hudson; Daniel M Green; Andrew M Davidoff Journal: Cancer Date: 2015-04-01 Impact factor: 6.860
Authors: Kelly R McMahon; Maya Harel-Sterling; Michael Pizzi; Louis Huynh; Erin Hessey; Michael Zappitelli Journal: Pediatr Nephrol Date: 2018-09-14 Impact factor: 3.714
Authors: Daniel M Green; Mingjuan Wang; Matthew J Krasin; Andrew M Davidoff; DeoKumar Srivastava; Dennis W Jay; Kirsten K Ness; Barry L Shulkin; Sheri L Spunt; Deborah P Jones; Jennifer Q Lanctot; Kyla C Shelton; Rachel C Brennan; Daniel A Mulrooney; Matthew J Ehrhardt; Todd M Gibson; Beth A Kurt; Leslie L Robison; Melissa M Hudson Journal: Pediatr Blood Cancer Date: 2020-07-24 Impact factor: 3.167
Authors: Ilona A Dekkers; Karin Blijdorp; Karlien Cransberg; Saskia M Pluijm; Rob Pieters; Sebastian J Neggers; Marry M van den Heuvel-Eibrink Journal: Clin J Am Soc Nephrol Date: 2013-02-14 Impact factor: 8.237
Authors: E Sieswerda; R L Mulder; I W E M van Dijk; E C van Dalen; S L Knijnenburg; H J H van der Pal; M S Mud; R C Heinen; H N Caron; L C M Kremer Journal: J Cancer Surviv Date: 2013-04-30 Impact factor: 4.442
Authors: Todd M Gibson; Zhenghong Li; Daniel M Green; Gregory T Armstrong; Daniel A Mulrooney; DeoKumar Srivastava; Nickhill Bhakta; Kirsten K Ness; Melissa M Hudson; Leslie L Robison Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-11-22 Impact factor: 4.254
Authors: Daniel M Green; Mingjuan Wang; Matthew Krasin; DeoKumar Srivastava; Songul Onder; Dennis W Jay; Kirsten K Ness; William Greene; Jennifer Q Lanctot; Kyla C Shelton; Liang Zhu; Daniel A Mulrooney; Matthew J Ehrhardt; Andrew M Davidoff; Leslie L Robison; Melissa M Hudson Journal: J Am Soc Nephrol Date: 2021-03-02 Impact factor: 10.121